Passage Bio, Inc. (PASG)

Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $18.50 million. The enterprise value is -$19.74 million.

Market Cap	18.50M
Enterprise Value	-19.74M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 3.11 million shares outstanding. The number of shares has increased by 12.14% in one year.

Current Share Class	3.11M
Shares Outstanding	3.11M
Shares Change (YoY)	+12.14%
Shares Change (QoQ)	+0.41%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	38.00%
Float	2.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.40
P/TBV Ratio	0.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.54.

Current Ratio	3.74
Quick Ratio	3.55
Debt / Equity	0.54
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -83.73% and return on invested capital (ROIC) is -37.49%.

Return on Equity (ROE)	-83.73%
Return on Assets (ROA)	-33.63%
Return on Invested Capital (ROIC)	-37.49%
Return on Capital Employed (ROCE)	-89.38%
Revenue Per Employee	n/a
Profits Per Employee	-$1.06M
Employee Count	60
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.32% in the last 52 weeks. The beta is 1.67, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.67
52-Week Price Change	-68.32%
50-Day Moving Average	7.57
200-Day Moving Average	10.34
Relative Strength Index (RSI)	38.74
Average Volume (20 Days)	37,648

Short Selling Information

The latest short interest is 1.78 million, so 57.19% of the outstanding shares have been sold short.

Short Interest	1.78M
Short Previous Month	1.78M
Short % of Shares Out	57.19%
Short % of Float	71.09%
Short Ratio (days to cover)	5.04

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-60.94M
Pretax Income	-76.57M
Net Income	-63.46M
EBITDA	-58.46M
EBIT	-60.94M
Earnings Per Share (EPS)	-$20.52

Balance Sheet

The company has $63.36 million in cash and $25.12 million in debt, giving a net cash position of $38.24 million or $12.31 per share.

Cash & Cash Equivalents	63.36M
Total Debt	25.12M
Net Cash	38.24M
Net Cash Per Share	$12.31
Equity (Book Value)	46.71M
Book Value Per Share	15.03
Working Capital	48.84M

Cash Flow

In the last 12 months, operating cash flow was -$42.87 million and capital expenditures -$34,000, giving a free cash flow of -$42.91 million.

Operating Cash Flow	-42.87M
Capital Expenditures	-34,000
Free Cash Flow	-42.91M
FCF Per Share	-$13.81

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.14%
Shareholder Yield	-12.14%
Earnings Yield	-342.95%
FCF Yield	-231.88%

Analyst Forecast

The average price target for Passage Bio is $153.33, which is 2,474.81% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$153.33
Price Target Difference	2,474.81%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	0.05:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1